PMID: 190 McBrideDADornNCYaoMJohnsonWTWangWBottiniNet al
Our systematic review found that GLP-1 RAs (such as exenatide, liraglutide, semaglutide, and the dual agonist tirzepatide) may significantly improve multiple facets of IIH: headaches, visual function, and induce substantial weight loss
[DOI] [PubMed] [Google Scholar] 187.Chimerel C., Emery E., Summers D.K., Keyser U., Gribble F.M., Reimann F
As the only diabetes treatment approved by the FDA to reduce the risk of cardiovascular death, JARDIANCE represents a tremendous step forward in our efforts to reduce the impact of heart disease among adults with type 2 diabetes and cardiovascular disease, said Paul Fonteyne, president and CEO, Boehringer Ingelheim Pharmaceuticals, Inc